Neurocrine Biosciences
NBIX
121 hedge funds and large institutions have $1.12B invested in Neurocrine Biosciences in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 54 increasing their positions, 23 reducing their positions, and 26 closing their positions.
135% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 23
105% more capital invested
Capital invested by funds: $547M → $1.12B (+$576M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
48% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $7.04M
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
3% more funds holding
Funds holding: 117 → 121 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$48.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$17.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$13.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.63M |
| 3 |
Millennium Management
New York
|
-$7.76M |
| 4 |
VM
VHCP Management
New York
|
-$6.69M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.47M |
NBIX Hedge Fund Activity: Q1 2014 in Review
121 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2014, worth a combined $1.12B — up 105% from $547M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new NBIX positions and 26 closed out — a net gain of 5 holders — while 54 added to existing stakes and 23 trimmed.
The largest buyer was OrbiMed, adding an estimated $48.2M. The largest seller was Invesco, cutting an estimated $13.9M.
- 121 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2014, up from 117 in Q4 2013.
- Funds reported $1.12B of Neurocrine Biosciences stock for Q1 2014, up 105% quarter-over-quarter.
- 31 funds opened new Neurocrine Biosciences positions in Q1 2014 and 26 closed out, a net change of +5 holders.
- The largest Neurocrine Biosciences buyer in Q1 2014 was OrbiMed, an estimated $48.2M added.
- The largest Neurocrine Biosciences seller in Q1 2014 was Invesco, an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2014.